Evaluation of Hydrocortisone Continuous Infusion Versus Intermittent Boluses in Resolution of Septic Shock.

PURPOSE To compare the effectiveness of continuous infusion of hydrocortisone versus intermittent boluses in the resolution of septic shock. METHODS A retrospective chart review was performed to investigate the effects of low-dose hydrocortisone continuous infusion (200 mg per day) versus intermittent boluses (50 mg every six hours) in septic shock patients who did not respond to fluid resuscitation and vasopressors. The primary outcome was time to resolution of shock, defined by time from the initiation of hydrocortisone to time of vasopressor withdrawal when mean arterial pressure was greater than 65 mm Hg. Hospital length of stay, intensive care unit (ICU) length of stay, 28-day all-cause in-hospital mortality, and hyperglycemia were secondary outcomes. RESULTS Of the 51 patients in the study, 33 received intermittent boluses of hydrocortisone. The median time to resolution of shock in the continuous group was three days, compared with a mean time of two days in the bolus group (P = 0.41). Mean hospital length of stay was 18.7 ± 19.4 days in the continuous group versus 18.6 ± 17.4 days in the bolus group (P = 0.77). Mean ICU length of stay was 10.4 ± 12.5 days in the continuous group versus 11.1 ± 9.2 days in the bolus group (P = 0.31). Thirteen patients (72%) in the continuous group died within 28 days, compared with 20 (60%) in the bolus group (P = 0.76). Five patients (28%) had hyperglycemic episodes after being given hydrocortisone in the continuous infusion group, compared with 20 patients (60%) in the bolus group (P = 0.04). CONCLUSION There was no significant difference in time to resolution of septic shock between continuous infusion (200 mg per day) and intermittent boluses (50 mg every six hours) of hydrocortisone. There were also no statistically significant differences in overall hospital length of stay, ICU length of stay, and 28-day all-cause in-hospital mortality. However, there was a significant difference in the incidence of hyperglycemia between the two groups, with patients in the bolus group experiencing more hyperglycemia than those in the continuous infusion group.